Considering the extreme heterogeneity of this tumor, we performed NGS analysis of a panel of genes in patients suffering from recurrent GBM, IDH-wildtype treated with regorafenib, to identify predictive factors for response to treatment. The gene discussed is IDH2; the disease is glioblastoma.